Home › Non-Small Cell Lung Cancer › Virginia › Alexandria
Pag-aaral pangklinika para sa Non-Small Cell Lung Cancer sa Alexandria, VA
Isang pag-aaral para sa Non-Small Cell Lung Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Alexandria. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Nagre-recruitPhase 3
- Kaiser Permanente-Caton Hill Medical Center, Woodbridge · 15 mi ang layo
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Nagre-recruitPhase 3
- Maryland Oncology Hematology, PA, Brandywine · 13 mi ang layo
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- Maryland Oncology Hematology, P.A., Brandywine · 13 mi ang layo
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Nagre-recruitPhase 3
- Research Site, Fort Belvoir · 8 mi ang layo
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Nagre-recruitPhase 2/3
- Local Institution - 007-814-A, Alexandria
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Nagre-recruitPhase 3
- Research Site, Brandywine · 13 mi ang layo
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- Research Site, Fort Belvoir · 8 mi ang layo
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Nagre-recruitPhase 3
- Inova Alexandria Hospital, Alexandria
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- Kaiser Permanente-Caton Hill Medical Center, Woodbridge · 15 mi ang layo
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2/3
- Kaiser Permanente-Caton Hill Medical Center, Woodbridge · 15 mi ang layo
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- Kaiser Permanente-Caton Hill Medical Center, Woodbridge · 15 mi ang layo
Pag-aaral para sa Non-Small Cell Lung Cancer sa ibang lungsod
- Houston, TX145 pag-aaral
- New York City, NY121 pag-aaral
- Arlington, VA104 pag-aaral
- Nashville, TN97 pag-aaral
- Boston, MA90 pag-aaral
- Los Angeles, CA87 pag-aaral
- St. Louis, MO73 pag-aaral
- Chicago, IL61 pag-aaral
- Baltimore, MD60 pag-aaral
- San Antonio, TX59 pag-aaral
- Columbus, OH57 pag-aaral
- Washington, DC55 pag-aaral
Iba pang pag-aaral sa Alexandria
- Kanser sa Baga7 pag-aaral
- Kanser sa Suso6 pag-aaral
- Type 2 Diabetes5 pag-aaral
- Atherosclerosis5 pag-aaral
- Sakit sa Puso at Ugat ng Dugo5 pag-aaral
- Colon Cancer4 pag-aaral
- Mataas na Presyon ng Dugo4 pag-aaral
- Obesity4 pag-aaral
- Kanser sa Tiyan3 pag-aaral
- Colorectal Cancer3 pag-aaral
- Overweight3 pag-aaral
- Stroke3 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.